CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 27 enrolled
Drug / intervention
Allopurinol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02956278
NCT02956278Phase 4Completed
CompareCT.gov

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

University of California, San Francisco·interventional·Posted Nov 7, 2016·Updated Jun 23, 2020

In Brief

A Phase 4 clinical trial evaluating Allopurinol and Placebo for Chronic Gout and Hyperuricemia. Completed, enrolled 27 participants across 1 site.

Detailed Summary

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Gout, Hyperuricemia
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Open Medicine Institute

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 7, 2016
Enrollment StartNov 1, 2016
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.7 years ago

Interventions

Allopurinoldrug

Placeboother

lactose placebo pill